Response—Evaluating human trials: FDA's role

Krause and Gruber offer the U.S. Food and Drug Administration (FDA) as part of the solution to the problems we have identified. We agree that the FDA could helpfully assist with the review of specific protocols for Zika human challenge trials (HCTs), especially given the need to update our panel's